Specialist Updates 
Oncology

Mystery over two triple-negative breast cancer trial results

Does the type of paclitaxel make a difference to outcomes?
Medicom Staff writer
0
23 September 2020
Save
Please login to bookmark Close
woman in pink top wearing pink ribbon to denote breast cancer

AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.

Results of two similar trials in people with triple-negative breast cancer appear to be contradictory, with no obvious explanation for why this should be, a conference has been told.

Delegates at the European Society for Medical Oncology (ESMO) virtual congress 2020 first heard from Dr Leisha Emens of the University of Pittsburgh, US, who presented results for overall survival (OS) in the IMpassion130 phase 3 trial.

In this pivotal trial, 902 patients with untreated locally advanced or metastatic triple-negative breast cancer were randomised to nab-paclitaxel with either the programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, or placebo.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .